Slingshot members are tracking this event:

Phase 2a data of Global Blood Therapeutics's(GBT) GBT440 in Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest expected Q4 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GBT Community voting in process

Additional Information

Additional Relevant Details page
Additional Relevant Details Update on 23 Oct 2017: GBT440 discontinued in the indication for Idiopathic Pulmonary Fibrosis.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 23, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2a, Gbt440, Hypoxemia, Idiopathic Pulmonary Fibrosis